We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Randomized Study of Positron Emission Tomography - Computed Tomography (PET/CT) in Pre-Operative Staging of Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00867412
Recruitment Status : Completed
First Posted : March 23, 2009
Last Update Posted : March 23, 2009
Danish Cancer Society
Danish Centre for Health Technology Assessment
Information provided by:
Rigshospitalet, Denmark

Brief Summary:
Patients with possible operable non-small cell lung cancer are randomised to conventional staging, or conventional staging and PET/CT. According to, patients with operable tumor will be referred to surgery, and the number of thoracotomies and futile thoracotomies wil be compared with the two groups in order to asses the possible benefit of PET/CT.

Condition or disease
Non-Small Cell Lung Cancer Thoracotomy

Detailed Description:

Patients with possible operable NSCLC after staging with CT are randomised to PET-CT with FDG or not, prior to mediastinoscopy. All patients are referred to mediastinoscopy unless a positive FDG uptake results in a positive biopsy suggesting stage IV disease.

Biopsies are performed according to the following criteria:

  1. Lymph nodes are numbered according the Mountain classification, and abnormal lesions must be confirmed histologically, by mediastinoscopy or thoracotomy.
  2. PET-positive lesions in the liver must be biopsied unless ultrasound or MRI unequivocally indicate the lesions are benign cysts or haemangioma.
  3. PET-negative adrenal lesions are accepted without biopsy if CT scan indicate the lesion is a benign adenoma.
  4. PET-positive bone lesions must be evaluated by plain x-ray, CT, MRI, or bone scintigraphy. In case of equivocal findings a biopsy must be performed.
  5. PET-positive brain lesions must be confirmed by CT or MRI.

Number of patients:

Patients with clinically operable NSCLC after CT-staging are included. All patients must have mediastinoscopy performed.

All patients referred to mediastinoscopy can be randomised after informed consent. A total of 430 consecutive, non-selected patients are planned. It is anticipated that approximately 60% of the referred patients with clinical stage I-IIIa NSCLC will undergo thoracotomy, and a risk of type I and II error of 5% and 10%, respectively, is accepted. Thus a total of 215 patients are randomised in each arm in order to observe an absolute difference of 15% in the number of thoracotomies. This number seems to be sufficient to evaluate differences in the secondary endpoints.

After inclusion of a total of 220 patients, corresponding to 110 PET-scans, an interim analyses are performed. In case of a highly significant difference in the number of thoracotomies (p < 0,001) the study will be closed.

Layout table for study information
Study Type : Observational
Actual Enrollment : 189 participants
Time Perspective: Prospective
Official Title: Randomized Study of PET/CT in Pre-Operative Staging of Lung Cancer
Study Start Date : January 2002
Actual Primary Completion Date : February 2007
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Conventional staging
Staging with CT, mediastinoscopy and bronchoscopy
Conventional staging and PET/CT
Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy

Primary Outcome Measures :
  1. Number of futile thoracotomies [ Time Frame: Within 1 year ]

Secondary Outcome Measures :
  1. Number of thoracotomies and survival [ Time Frame: Within 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with non-small cell lung cancer

Inclusion Criteria:

  1. Clinically operable NSCLC after CT
  2. Fit for thoracotomy and lobectomy or pneumectomy after lung function tests
  3. CT-scan of thorax, including liver and adrenals with no signs of distant metastases.
  4. No medical condition contraindication surgery.
  5. Age 18-80
  6. No claustrophobia.
  7. Negative pregnancy test.
  8. No diabetes mellitus.
  9. Signed informed consent.

Exclusion Criteria:

  1. Radiologically M1 disease.
  2. Pregnancy
  3. Known claustrophobia.
  4. Estimated FEV1 < 30% of expected after surgery.
  5. Diabetes mellitus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00867412

Layout table for location information
PET & Cyclotron Unit, Rigshospitalet,
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Danish Cancer Society
Danish Centre for Health Technology Assessment
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ulrik Lassen, MD., PH.D, Rigshospitalet
ClinicalTrials.gov Identifier: NCT00867412    
Other Study ID Numbers: PERALUST
First Posted: March 23, 2009    Key Record Dates
Last Update Posted: March 23, 2009
Last Verified: March 2009
Keywords provided by Rigshospitalet, Denmark:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases